RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:100991

Autosomal dominant spastic paraplegia type 10

low confidenceDisorder

Also known as: SPG10

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

2,234

Trials

0

Interventional, condition-specific

Researchers

1,509

Distinct authors in sample

Gene link

KIF5A

Strong

Readiness

4/6

Stages with a signal

Clinical definition (Orphanet)

A rare, spastic paraplegia that can present as either a pure or complex . The pure form is characterized by lower limb spasticity, hyperreflexia and extensor plantar responses, presenting in childhood or adolescence. The complex form is characterized by the association with additional manifestations including peripheral with upper limb muscle atrophy, moderate and parkinsonism. Deafness and retinitis pigmentosa have also been reported.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (4)

KIF5A hereditary spastic paraplegia · autosomal dominant spastic paraplegia type 10 · hereditary spastic paraplegia caused by mutation in KIF5A · hereditary spastic paraplegia type 10

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

4/6 stages with a signal

No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.

  1. Gene identifiedPresent

    Strong — KIF5A

  2. LiteraturePresent

    2,234 matched papers (1,606 in last 10 years) Source

  3. Phenotype characterisedPresent

    46 HPO annotations (e.g. Lower limb spasticity; Sensorimotor neuropathy; Spastic paraparetic gait) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialPartial

    None under the specific name; 104 for broader category paraplegia

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (KIF5A).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

46

Associated phenotypes · MONDO:0011408

  • Lower limb spasticity
  • Sensorimotor neuropathy
  • Spastic paraparetic gait
  • Ankle clonus
  • Scoliosis

Showing 5 of 46 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

2,234

2,234 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

2,234 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

1,606 in the last 10 years · low confidence

Phrase hits: 285 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,509

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Bassi MT8 papers · 2025

    IRCCS E. Medea, Laboratory of Molecular Biology, Bosisio Parini Lecco, Italy.

    Papers in Europe PMC
  2. 02
    Schöls L8 papers · 2025

    Department of Neurodegenerative Diseases Hertie-Institute for Clinical Brain Research and Center of Neurology University of Tübingen Hoppe-Seyler-Str. 3 72076 Tübingen Germany.

    Papers in Europe PMC
  3. 03
    Blackstone C7 papers · 2024

    Cell Biology Section, Neurogenetics Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Building 35, Room 2A-201, 9000 Rockville Pike, Bethesda, MD 20892, USA. Electronic address: blackstc@ninds.nih.gov.

    Papers in Europe PMC
  4. 04
    Martinuzzi A7 papers · 2024

    Medea Scientific Institute (A.M., M.V., G.P.), Conegliano and Bosisio Parini, Treviso, Italy.

    Papers in Europe PMC
  5. 05
    Schüle R7 papers · 2024

    Department of Neurodegenerative Diseases Hertie-Institute for Clinical Brain Research and Center of Neurology University of Tübingen Hoppe-Seyler-Str. 3 72076 Tübingen Germany.

    Papers in Europe PMC
  6. 06
    Stevanin G7 papers · 2021

    Institut du Cerveau-Paris Brain Institute-ICM, INSERM, CNRS, APHP, Sorbonne Université, Pitié-Salpêtrière Hospital, 75013 Paris, France.

    Papers in Europe PMC
  7. 07
    Orlacchio A6 papers · 2026

    Dipartimento di Medicina e Chirurgia, Università di Perugia, 06132 Perugia, Italy.

    Papers in Europe PMC
  8. 08
    Ratti A6 papers · 2026

    Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy; Department of Pathophysiology and Transplantation, "Dino Ferrari" Center - Università degli Studi di Milano, Milan 20122, Italy.

    Papers in Europe PMC
  9. 09
    Takiyama Y6 papers · 2022

    Department of Neurology, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi.

    Papers in Europe PMC
  10. 10
    Taroni F6 papers · 2026

    Unit of Genetics of Neurodegenerative and Metabolic Diseases, Fondazione IRCCS Istituto Neurologico "Carlo Besta," Milan 20133, Italy.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 104 trials are registered for paraplegia, the broader category — shown separately because they may or may not enrol this specific subtype.

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

low confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

104 interventional trials matched paraplegia, the broader category — listed below. Those studies are not counted in the condition-specific total.

Broader category: paraplegia

104

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Worth raising with a clinician. How we count trials.

Recruiting under the broader category

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for Autosomal dominant spastic paraplegia type 10 — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("Autosomal dominant spastic paraplegia type 10" OR "SPG10" OR "KIF5A hereditary spastic paraplegia" OR "hereditary spastic paraplegia caused by mutation in KIF5A" OR "hereditary spastic paraplegia type 10") OR (MESH:"Spastic paraplegia 10, autosomal dominant") OR ("KIF5A" OR "KIF5A syndrome" OR "KIF5A-related")

Run this search on Europe PMC

MeSH descriptor terms unioned into the query: Spastic paraplegia 10, autosomal dominant

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Autosomal dominant spastic paraplegia type 10" OR "SPG10" OR "KIF5A hereditary spastic paraplegia" OR "hereditary spastic paraplegia caused by mutation in KIF5A" OR "hereditary spastic paraplegia type 10" OR "Spastic paraplegia 10, autosomal dominant"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"paraplegia"

Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (2234) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-27T07:09:08.435Z